ACI is excited to return to Washington, D.C. with our one-of-a-kind, interactive forum where stakeholders can gather with peers, discuss challenges, and walk away with tailored strategies for overcoming these challenges.

Federal and state authorities continue to go after opioid manufacturers, distributors, pharmacies, pharmacists, physicians, nurses, and every entity that forms a link in the supply chain, with relentless pursuit. Now is the time to ensure you are best prepared to respond and minimize potential risk so you are ready when your company/client is targeted.

ACI’s Summit on Controlled Substances is your opportunity to gather and network with your peers and discuss effective strategies you can implement to properly respond to investigations and assist with combating the opioid abuse epidemic.

Hear from the Experts

Our faculty consisting of current and former DEA officials, DOJ representatives, in-house industry counsel, and outside counsel, will provide an up-to-date analysis of the current regulations, best practices for staying compliant, avoiding DEA investigations, and knowing how to respond when DEA comes knocking at your door.

Get governments insights on the complex challenges facing all entity:

Stacy Harper-Avilla
Section Chief, UN Reporting & Quota Section – Diversion Control Division
Drug Enforcement Administration

James A. Arnold
Liaison and Policy Section Chief – Diversion Control Division
Drug Enforcement Administration

Erica Liu
Chief, Opioid Abuse Prevention and Enforcement Unit, Assistant U.S. Attorney
U.S. Attorney’s Office- District of New Jersey

William T. “Tim” McDermott
Special Agent in Charge, Denver Division
Drug Enforcement Administration

Brian McKnight
Special Agent in Charge, Chicago Division
Drug Enforcement Administration

Elliot M. Schachner
Assistant U.S. Attorney
U.S. Attorney’s Office- Eastern District of New York

Hear from distinguished in-house leaders:

Amanda Glover, Pharm.D.
VP, Regulatory Affairs
DMEPOS Compliance Officer
Rite Aid Corp.

Selin Hoboy
VP Legislative and Regulatory Affairs

Wilbert Plummer
Director, DEA Compliance
& Corporate Security
Amneal Pharmaceuticals
Former Special Agent in Charge, New York Enforcement Division Drug Enforcement Administration

Joseph Shepherd
Head of North America Distribution Regulatory Compliance
Mylan Pharmaceutical
Former Assistant Special Agent in Charge and Diversion Program Manager, New Orleans Field Division Drug Enforcement Administration

Featuring tailored solutions to the many challenges such as:

  • Understanding your responsibility and ensuring compliance with the evolving Know Your Customer and Suspicious Order Monitoring requirements
  • Appreciating the ramifications of recent state and federal enforcement actions
  • Tracking the MDL and related litigations and the resulting industry effects
  • Organizing and preparing for a DEA facility inspection and avoiding fines
  • Assessing your internal policies and making the proper adjustments in light of DEA’s Final Controlled Substances Quotas Regulation


Attend this event and you will gain necessary skills and strategies to rise to the ever-evolving challenges of this vital topic. Seats are selling out quickly. Register today!


Here’s what some of our attendees had to say about our inaugural event:

“This conference was spot on with the issues we are facing everyday.” Amy D’Anna
Novartis Institutes for Biomedical Research

“It was great to hear from current and former industry leaders and experts from DEA, US AG offices, FDA, etc. Hearing about the current events and upcoming trends/expectations was valuable.” Jaime McDermott
Kroger Health

“As the Director of Compliance for IPC, I was extremely pleased with last year’s speakers and the insight they provided into the latest controlled substance regulations.” Brian Rucker
Independent Pharmacy Cooperative


“The PIL Task force will focus . . . on targeting opioid manufacturers and distributors . . . we will use criminal penalties, we will use civil penalties, we will use whatever tools we have to hold people accountable for breaking our laws.”

– U.S. Attorney General,
Jeff Sessions
February 2018

Event Contacts

For sponsorship opportunities please contact:
Ken Glass
Tel: 212-352-3220 ext. 7409
[email protected]

For media partnership opportunities please contact:
Linda Lam
Tel: 212-352-3220 ext. 5538
[email protected]

For questions about this year’s program/content, or information on how you can speak next year please contact:
Lisa Piccolo
Tel: 212-352-3220 ext. 5229
[email protected]

Connect With Us